DUBLIN, Oct. 18, 2023 /PRNewswire/ -- Alkermes plc
(Nasdaq: ALKS) will host a conference call and webcast presentation
at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, Oct. 25, 2023 to discuss the company's
third quarter financial results as well as initial clinical data
related to ALKS 2680, the company's novel, investigational orexin 2
receptor agonist in development for the treatment of narcolepsy,
that will be presented at World Sleep Congress.
The webcast player and accompanying slides may be accessed on
the Investors section of Alkermes' website at www.alkermes.com. The
conference call may be accessed by dialing +1 877 407 2988 for U.S.
callers and +1 201 389 0923 for international callers. A replay of
the webcast will be available approximately two hours after the
completion of the event and may be accessed by visiting Alkermes'
website.
About Alkermes plc
Alkermes plc is a
fully-integrated, global biopharmaceutical company developing
innovative medicines in the fields of neuroscience and oncology.
The company has a portfolio of proprietary commercial products
focused on alcohol dependence, opioid dependence,
schizophrenia and bipolar I disorder, and a pipeline of product
candidates in development for neurological disorders and cancer.
Headquartered in Dublin, Ireland, Alkermes has a
research and development center
in Waltham, Massachusetts; a research and manufacturing
facility in Athlone, Ireland; and a manufacturing facility
in Wilmington, Ohio. For more information, please visit
Alkermes' website at www.alkermes.com.
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
Logo -
https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/alkermes-to-report-third-quarter-financial-results-on-october-25-2023-301960879.html